MARC RAAD: Open Payments
NPI 1316085665 · WOLCOTT, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,325 in 146 payments from 34 companies in 2025. Trend: 2023 $3,230 · 2024 $4,270 · 2025 $3,325
Food & beverage: $3,325
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 10 | $380 |
| Vanda Pharmaceuticals Inc. | 14 | $378 |
| Ardelyx, Inc. | 14 | $297 |
| Lilly USA, LLC | 10 | $243 |
| Novo Nordisk Inc | 11 | $207 |
| Otsuka America Pharmaceutical, Inc. | 8 | $193 |
| Bayer Healthcare Pharmaceuticals Inc. | 7 | $167 |
| Sumitomo Pharma America, Inc. | 8 | $147 |
| ABBVIE INC. | 12 | $138 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $131 |
Products named: IBSRELA, FANAPT, JARDIANCE, REXULTI, Kerendia, LOKELMA, Ozempic, HETLIOZ.
Industry payments across CT — which companies pay providers there.
